CYL Stock Overview
Manufactures, processes, and distributes medical devices and implantable human tissues worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Artivion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.00 |
| 52 Week High | US$27.20 |
| 52 Week Low | US$15.20 |
| Beta | 1.75 |
| 11 Month Change | 10.20% |
| 3 Month Change | 14.16% |
| 1 Year Change | 68.75% |
| 33 Year Change | 77.63% |
| 5 Year Change | 21.62% |
| Change since IPO | 558.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| CYL | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 7.6% | 2.9% | 0.8% |
| 1Y | 68.8% | -4.7% | 8.6% |
Return vs Industry: CYL exceeded the German Medical Equipment industry which returned -5% over the past year.
Return vs Market: CYL exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| CYL volatility | |
|---|---|
| CYL Average Weekly Movement | 3.8% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CYL has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: CYL's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,500 | Pat Mackin | artivion.com |
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms.
Artivion, Inc. Fundamentals Summary
| CYL fundamental statistics | |
|---|---|
| Market cap | €1.14b |
| Earnings (TTM) | -€803.69k |
| Revenue (TTM) | €367.39m |
3.1x
P/S Ratio-1,427x
P/E RatioIs CYL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYL income statement (TTM) | |
|---|---|
| Revenue | US$384.90m |
| Cost of Revenue | US$136.53m |
| Gross Profit | US$248.37m |
| Other Expenses | US$249.22m |
| Earnings | -US$842.00k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.02 |
| Gross Margin | 64.53% |
| Net Profit Margin | -0.22% |
| Debt/Equity Ratio | 103.0% |
How did CYL perform over the long term?
See historical performance and comparison